Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$20 Mln
P/E Ratio
--
P/B Ratio
0.48
Industry P/E
--
Debt to Equity
0
ROE
-0.25 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-0.35
CFO
$-161.57 Mln
EBITDA
$-189.75 Mln
Net Profit
$-187.54 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Sol-Gel Technologies - ADR
| -15.90 | 37.13 | -11.70 | -14.98 | -52.63 | -37.54 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|
|
Sol-Gel Technologies - ADR
| -75.77 | -38.38 | -24.41 | -42.92 | 184.88 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2.22 | 25.43 | -- | -79.46 | |
| 1.48 | 138.40 | -- | -23.63 | |
| 2.40 | 109.01 | -- | -103.34 | |
| 9.87 | 466.01 | -- | 342.83 |
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the... treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. Address: 7 Golda Meir Street, Ness Ziona, Israel, 7403650 Read more
Co-Founder, CEO & Director
Dr. Alon Seri-Levy
Co-Founder, CEO & Director
Dr. Alon Seri-Levy
Headquarters
Ness Ziona
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Sol-Gel Technologies Ltd - ADR stood at $ 50 Mln as on 30-Sep-24
The share price of Sol-Gel Technologies Ltd - ADR is $0.78 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Sol-Gel Technologies Ltd - ADR has given a return of -52.63% in the last 3 years.
Sol-Gel Technologies Ltd - ADR has a market capitalisation of $ 20 Mln as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Sol-Gel Technologies Ltd - ADR is 0.48 times as on 24-Apr-2025, a 80% discount to its peers’ median range of 2.45 times.
Since, TTM earnings of Sol-Gel Technologies Ltd - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sol-Gel Technologies Ltd - ADR and enter the required number of quantities and click on buy to purchase the shares of Sol-Gel Technologies Ltd - ADR.
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. Address: 7 Golda Meir Street, Ness Ziona, Israel, 7403650
The CEO & director of Dr. Alon Seri-Levy. is Sol-Gel Technologies Ltd - ADR, and CFO & Sr. VP is Dr. Alon Seri-Levy.
There is no promoter pledging in Sol-Gel Technologies Ltd - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
48
|
|
|
15
|
|
|
8
|
|
|
5
|
| Sol-Gel Technologies Ltd. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-28.42
|
|
Operating margin(%)
|
-87.17
|
|
Net Margin(%)
|
-81.75
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Sol-Gel Technologies Ltd - ADR was $0 Mln.
$0.01
(
